Download PDF

1. Company Snapshot

1.a. Company Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.


Enanta Pharmaceuticals, Inc.was founded in 1995 and is headquartered in Watertown, Massachusetts.

Show Full description

1.b. Last Insights on ENTA

Enanta Pharmaceuticals' recent performance was negatively impacted by a Q1 loss of $1.05 per share, although it topped revenue estimates. However, the company's earnings beat was offset by a higher-than-expected loss, which may raise concerns about its profitability. On the positive side, Enanta has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade

Nov -21

Source: zacks.com

Card image cap

Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development

Nov -19

Source: seekingalpha.com

Card image cap

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov -04

Source: businesswire.com

Card image cap

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Oct -07

Source: businesswire.com

Card image cap

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Oct -01

Source: benzinga.com

Card image cap

Enanta Pharmaceuticals, Inc. - Special Call

Sep -29

Source: seekingalpha.com

Card image cap

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Sep -29

Source: seekingalpha.com

Card image cap

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Sep -29

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Small Molecule Drugs

Expected Growth: 9.27%

Enanta Pharmaceuticals' small molecule drugs segment growth of 9.27% is driven by increasing demand for Hepatitis B and C treatments, strong pipeline of novel core inhibitors, and strategic partnerships. Additionally, growing awareness of viral diseases, expanding healthcare infrastructure, and favorable regulatory environments contribute to the segment's growth.

7. Detailed Products

Viekira Pak

A medication used to treat chronic hepatitis C virus (HCV) genotype 1 infection

Viekira XR

An extended-release tablet formulation of Viekira Pak, used to treat chronic hepatitis C virus (HCV) genotype 1 infection

Paritaprevir

A protease inhibitor used in combination with other medications to treat chronic hepatitis C virus (HCV) genotype 1 infection

Ritonavir

A pharmacokinetic enhancer used to boost the levels of other medications, including paritaprevir, in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection

Dasabuvir

A non-nucleoside polymerase inhibitor used in combination with other medications to treat chronic hepatitis C virus (HCV) genotype 1 infection

Ombitasvir

A NS5A inhibitor used in combination with other medications to treat chronic hepatitis C virus (HCV) genotype 1 infection

8. Enanta Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Enanta Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for hepatitis C and other diseases.

Bargaining Power Of Customers

Enanta Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the presence of insurance companies and government programs that reimburse for treatments.

Bargaining Power Of Suppliers

Enanta Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and the company's dependence on a few key suppliers.

Threat Of New Entrants

Enanta Pharmaceuticals, Inc. has a high threat of new entrants due to the attractiveness of the hepatitis C market and the presence of several companies developing new treatments.

Intensity Of Rivalry

Enanta Pharmaceuticals, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 10.90%
Debt Cost 6.66%
Equity Weight 89.10%
Equity Cost 6.66%
WACC 6.66%
Leverage 12.23%

11. Quality Control: Enanta Pharmaceuticals, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fennec Pharmaceuticals

A-Score: 6.0/10

Value: 8.2

Growth: 8.6

Quality: 6.4

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Sage Therapeutics

A-Score: 4.9/10

Value: 7.4

Growth: 6.1

Quality: 4.8

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Synlogic

A-Score: 4.8/10

Value: 7.2

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Genelux

A-Score: 3.2/10

Value: 6.0

Growth: 4.2

Quality: 3.6

Yield: 0.0

Momentum: 4.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
SAB Biotherapeutics

A-Score: 3.1/10

Value: 8.8

Growth: 1.2

Quality: 6.9

Yield: 0.0

Momentum: 1.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Enanta Pharmaceuticals

A-Score: 2.8/10

Value: 7.2

Growth: 1.2

Quality: 3.9

Yield: 0.0

Momentum: 4.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

14.85$

Current Price

14.85$

Potential

-0.00%

Expected Cash-Flows